'Doctor, will this medicine give me cancer?': lessons from nitrosamines and extended-release metformin.

The withdrawal in the USA of metformin extended-release formulations [1,2] due to a contaminant with carcinogenic potential has raised concerns. An impurity from the manufacturing process has been implicated, which has been found only in the extended-release and not in the immediate-release metformin formulations.